Back to top

gene-therapy: Archive

Zacks Equity Research

Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates

SRPT posts a wider Q4 loss as Elevidys sales tumble, but revenues top estimates and 2026 guidance outlines a cautious recovery path.

RHHBYPositive Net Change SRPTNegative Net Change ARWRNegative Net Change